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Purpose: AURA was an international, retrospective, observational study that monitored the 
real-life use and effectiveness of ranibizumab injections in patients with neovascular age-related 
macular degeneration (nAMD). This paper reports the findings from the UK.
Methods: Patients who started treatment with ranibizumab between January 1, 2009, and 
August 31, 2009, and had documented follow-up to the end of their treatment and/or monitoring 
or until August 31, 2011, were retrospectively monitored; the diagnosis and subsequent decision 
to treat was made by the patient’s own physician. Assessments included the change in visual 
acuity (standardized letter count) during the first and second years after start of ranibizumab 
therapy and resource utilization.
Results: Four hundred and ten patients from 13 UK centers were analyzed. The mean (standard 
deviation [SD]) letter score at baseline was 55.0 (17.8). The mean (SD) change in visual acuity 
from baseline was +6.0 (15.4) letters at year 1 and +4.1 (16.9) at year 2. Most of the patients 
(86.6%) completed a 3-month loading phase; the visual improvements were numerically 
higher in these patients. Over 2 years, the mean (SD) number of clinic visits and injections 
was 18.4 (5.0) and 9.0 (4.7), respectively. Resource use and visual acuity gains were greater 
than those observed in the global population, which included other countries enrolled in AURA 
(Canada, France, Germany, Ireland, Italy, the Netherlands, and Venezuela). When patients were 
stratified according to severity of nAMD (based on letter count at baseline), the mean change in 
visual acuity score at years 1 and 2 was also higher for the UK than for the global population 
across all subgroups.
Conclusion: Monitoring and treatment rates were high in the UK, resulting in better visual 
acuity outcomes compared with other included countries. This suggests that translation of clini-
cal study outcomes into real-life settings is achievable, but at the expense of higher resource 
utilization than is currently the norm in most developed countries.
Keywords: neovascular or wet age-related macular degeneration, anti-vascular endothelial 
growth factor
Introduction
The current standard of care for neovascular age-related macular degeneration 
(nAMD) is treatment with agents (such as ranibizumab) that inhibit vascular 
endothelial growth factor (VEGF), a potent angiogenic mediator associated with 
age-dependent choroidal neovascularization.1 Ranibizumab was approved for use in 
nAMD largely due to the findings from two pivotal clinical studies.2,3 In these studies, 
monthly ranibizumab (0.3 or 0.5 mg) was shown to be superior to sham or photody-
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namic therapy for the 12-month primary efficacy outcome, 
and visual and anatomical benefits were sustained over a 
24-month follow-up.2–4 Based on these studies, monthly 
dosing with ranibizumab was recommended.5 However, this 
approach can be unsustainable in many clinical practices. 
Less frequent dosing is now the norm, and the label for all 
the currently available anti-VEGF agents recommends an 
initial loading phase followed by as-needed (PRN) dosing 
with frequent monitoring.5,6 
However, it is acknowledged that PRN or quarterly dos-
ing may be less effective compared with monthly dosing, and 
optimal regimens need to be established.7–11 Some studies 
show that the visual benefit declines during the maintenance 
phase despite an initial marked improvement in acuity at 
the completion of the loading phase.7,8,10,11 In contrast, the 
SUSTAIN study found that ranibizumab PRN was compa-
rable with monthly dosing.12 
The AURA study was undertaken to monitor ranibizumab 
use and treatment outcomes in a real-life setting. AURA 
was a large, retrospective study conducted in eight countries 
(Canada, France, Germany, Ireland, Italy, the Netherlands, 
the UK, and Venezuela) that evaluated the real-life clini-
cal use of ranibizumab treatment for patients with nAMD 
who were diagnosed and treated by their own physicians.13 
In the global population (all eight included countries), there 
was a mean increase in visual acuity of +2.4 letters during 
year 1, which decreased to +0.6 letters during year 2. Patients 
received approximately seven injections over a 2-year period, 
but there was variability between countries. The findings 
also indicated that monitoring strategies and retreatment 
frequencies varied between countries, which may explain 
the poorer visual outcomes in the overall AURA population. 
The aim of the present report is to describe the outcomes of 
the UK cohort of AURA and to compare with the global 
AURA cohort (Canada, France, Germany, Ireland, Italy, the 
Netherlands, and Venezuela).
Materials and methods
study design and participants
The study design has been reported elsewhere.13 In 
brief, patients who were diagnosed with nAMD and 
given ranibizumab injections during January 1, 2009 to 
August 31, 2009 were eligible; the diagnosis and subsequent 
decision to treat was made by the patient’s own physician. 
For inclusion, patients were required to have received one 
or more ranibizumab injections with documented follow-up 
to the end of their treatment and/or monitoring, or until 
August 31, 2011, whichever came first (Figure S1). Patients 
who switched to bevacizumab or pegaptanib sodium, but 
received ranibizumab at some point, remained in the study. 
Only one eye was included per patient, which was defined 
as the eye treated at the start of ranibizumab therapy. In 
patients with bilateral disease, the eye with the worst visual 
acuity was included. Patients taking part in an investigational 
study of any other drug or device were excluded. Approval 
from the country-specific independent ethics committees 
or institutional review boards was received based on the 
requirements of local law and/or regulations, and written 
consent was obtained from each patient prior to inclusion. 
We certify that all applicable institutional and governmental 
regulations concerning the ethical use of human volunteers 
were followed during this research. This paper reports the 
findings from the UK cohort only, but makes explicit com-
parisons with the global results.
assessments
All data, including demographics, were collected ret-
rospectively from patients’ medical records (paper or 
electronic), which included results from examinations 
performed during routine clinical practice. The primary 
assessment was the mean change in visual acuity over 
the 2-year period (with key assessments at year 1 [day 
360] and year 2 [day 720]) after the start of ranibizumab 
treatment. As the study was observational, visual acuity 
was measured using a variety of vision charts, but was 
converted to a standardized visual acuity scoring system 
(letter count). The conversion chart used is provided in the 
online Supplementary material for the primary manuscript.13 
Secondary assessments included resource utilization dur-
ing the 2-year period (ie, the number of clinic visits, use 
of optical coherence tomography [OCT] and visual acuity 
tests, and the number of injections).
statistical analysis
The study was explorative, and all the analyses are descrip-
tive. The mean change in visual acuity over the 2-year period 
was calculated for patients who received one or more doses 
of ranibizumab treatment and had one or more post-baseline 
assessments of visual acuity for the treated eye. This was 
defined as the effectiveness analysis set, and it was estimated 
that a guiding sample size of 399 subjects per country was 
required to estimate the change from baseline in the standard-
ized visual acuity score within a 95% confidence interval (CI) 
of ±1.5 letters. Mean change in visual acuity was assessed 
using a last observation carried forward (LOCF) analysis 
to account for missing data. Secondary assessments were 
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analyzed using frequency tables or summary statistics and 
were also performed using the effectiveness analysis set.
Results
Participants
A total of 774 patients were screened, and 461 of these were 
enrolled from 13 centers in the UK. A total of 313 patients 
were excluded for the following reasons: participation in 
an investigational study (n=40), no diagnosis of nAMD 
(n=3), no informed consent form signed (n=257), and start 
of ranibizumab therapy outside inclusion dates (n=13). Of 
the enrolled patients, 410 received one or more doses of 
ranibizumab, had one or more post-baseline measurements 
of visual acuity for the treated eye, and were included in 
the effectiveness analysis set (thus meeting the prespecified 
sample size of 399 subjects).
The baseline characteristics of patients included in the 
effectiveness analysis sets in the UK and global cohorts 
are shown in Table 1. The cohorts were well-matched with 
regard to age, sex, OCT volume (center point thickness), 
and mean visual acuity (letter count) at baseline. Although 
the aim of the study was to follow patients receiving 
ranibizumab treatment, five patients received at least one 
injection of bevacizumab and one patient received one 
injection of pegaptanib sodium. The majority of patients 
(99.3% overall: 99.8% at year 1 and 99.5% at year 2) did 
not receive any treatment change. Three patients switched 
from ranibizumab to bevacizumab due to nonresponse (n=2) 
and reason not known (n=1). 
Change in visual acuity over time
Visual acuity (letter count) improved from baseline follow-
ing initiation of ranibizumab treatment, peaking at day 270 
with a mean (standard deviation [SD]) gain in visual acuity 
of +6.5 (14.4) letters in the overall UK cohort. The mean (SD) 
change in visual acuity from baseline was +6.0 (15.4) letters 
at year 1, but there was a small decline in visual acuity over 
time, and the mean (SD) change was +4.1 (16.9) at year 2 
in the UK cohort (Figure 1A). 
The majority of patients in the UK cohort (355/410; 
86.6%) received a loading phase (ie, first three ranibizumab 
injections within 90 days). The mean change in visual acuity 
was greater in these patients compared with patients who did 
not receive a loading phase; however, a small decline in visual 
acuity was observed during the follow-up in both groups 
(Figure 1A). The mean change in visual acuity from baseline 
was +6.8 (15.5) letters in year 1 and +4.8 (17.1) letters in year 
2 in patients receiving a loading phase, and +0.5 (13.7) and 
-0.2 (14.3) in patients who did not receive a loading phase.
The mean improvement in visual acuity was also greater 
in the UK compared with the global population (Figure 1B); 
there was a decline in both the UK and global populations, 
but this occurred earlier in the global population (from 
approximately day 120 onward) and was more marked. 
Compared with the other countries enrolled in AURA, the 
UK demonstrated the greatest visual acuity improvements 
over time, followed by the Netherlands (Figure 1C).
When patients were stratified according to severity of 
nAMD (based on letter count at baseline), the mean change 
in visual acuity score at years 1 and 2 was higher for the UK 
than for the global population (Figure 2). In the UK, mean 
(SD) improvement in visual acuity was also higher in patients 
with a baseline score of ,35 letters (+15.1 [16.9] at year 1 
and +11.6 [16.9] at year 2) (Figure 2). 
resource utilization
Overall, 43.4% of patients in the UK cohort received ranibi-
zumab treatment within 2 weeks of receiving their nAMD 
diagnosis (Figure 3), and the mean (SD) treatment duration 
was 634.7 (292.4) days. In the UK cohort, the mean (SD) 
number of visits to the ophthalmologist was 18.4 (5.0) over 
Table 1 Patient demographics at baseline in the UK and global 
population (effectiveness analysis set)
UK,
n=410
Global,
N=2,227
age at treatment start, yearsa
Mean (sD) 77.7 (7.5) 76.9 (8.2)
sex
Male, n (%)
Female, n (%)
163 (39.8)
247 (60.2)
878 (39.4) 
1,349 (60.6)
eye affected by naMD
right, n (%)
left, n (%)
right and left, n (%)
166 (40.5)
162 (39.5)
82 (20.0)
956 (42.9)
937 (42.1)
334 (15.0)
OCT volume – thickness center point, μmb
Mean (sD) 336.5 (114.3) 334.4 (113.6)
Visual acuity ranges, lettersc
$65, n (%)
$55-,65 letters, n (%)
$35-,55 letters, n (%)
,35 letters, n (%)
Missing, n (%)
Visual acuity, letters 
Baseline, mean (sD)
Year 1, mean (sD)
Year 2, mean (sD)
137 (33.4)
101 (24.6)
132 (32.2)
38 (9.3)
2 (0.5)
55.0 (17.8)
60.8 (20.0)
59.0 (20.9)
858 (38.5)
435 (19.5)
645 (29.0)
209 (9.4)
80 (3.6)
55.4 (18.4)
57.3 (20.6)
55.4 (21.5)
Notes: an=2,185 (global); bn=197 (UK) and n=690 (global); cpatients included in 
effectiveness analysis set based on mean letter score at baseline. 
Abbreviations: naMD, neovascular age-related macular degeneration; OCT, 
optical coherence tomography; sD, standard deviation.
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Figure 1 Mean change in visual acuity score (letter count) from baseline over time for the (A) UK cohort (including loading phase subgroups); (B) UK cohort versus global 
aUra; and (C) global aUra (country breakdown).
Notes: Data are based on effectiveness analysis set using an lOCF approach. loading phase includes patients who received three injections over a 3-month (90-day) period. 
(C) adapted by permission from BMJ Publishing group limited. British Journal of Ophthalmology. Multi-country real-life experience of anti-vascular endothelial growth factor 
therapy for wet age-related macular degeneration. holz Fg, Tadayoni r, Beatty s, et al. 2015;99(2):220–226. Copyright © 2015, British Medical Journal Publishing group.13
Abbreviation: lOCF, last observation carried forward.
?
????
??
??
?
?
?
?
?
??
??
?
?
?
?
?
??
??
?
?
?
?
?
? ?? ?? ?? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ???
? ?? ?? ?? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ???
? ?? ?? ?? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ???
????
???????
????
???
????
????
?????
????
??
????
????
????
????
???
?????
????
??
???
????
???
????
????
?????
????
??
????
????
????
????
???
?????
????
??
???
????
???
????
????
?????
????
??
????
????
????
????
???
?????
????
??
?
?
???????????????????????????? ?????????????????????????? ????????????????
???????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????
?????????? ??????????????????????????????????????
Clinical Ophthalmology 2016:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
91
real-life utilization of ranibizumab for naMD in the UK
the full 2-year observation period (Figure 4A). There was 
a higher mean (SD) number of visits in the first year (10.4 
[2.2]) than in the second year (8.0 [3.3]). Similar findings 
were observed for the mean (SD) number of visual acuity 
tests (10.0 [2.4] in year 1 and 7.8 [3.3] in year 2) and OCT 
tests (9.2 [2.4] in year 1 and 7.4 [3.0] in year 2) (Figure 4A). 
Patients from the UK received a mean (SD) of 9.0 (4.7) injec-
tions during the full 2-year period (5.8 [2.4] in year 1 and 3.2 
[2.8] in year 2) (Figure 4A). There were more visits, tests, 
and injections in the UK compared with the global popula-
tion during year 1 and year 2 (Figure 4B and C). The mean 
number of injections in the UK compared with the global 
population (excluding the UK) was 5.8 versus 4.8 in year 1 
and 3.2 versus 2.0 in year 2.
In the global cohort, 80.2% (n=1,786/2,227) completed 
a 3-month loading phase, and 19.9% (355/1,786) of these 
patients were from the UK. The mean (SD) time from the end 
of the loading phase to the next injection (maintenance phase) 
was 102.8 (121.4) days in the UK and 134.0 (141.2) days 
in the global cohort (excluding the UK). The mean (SD) 
duration between visits in the maintenance phase was 42.1 
(11.7) days in the UK compared with 59.3 (51.0) in the global 
cohort (excluding the UK). The mean (SD) duration between 
injections in the maintenance phase was 100.0 (80.3) in the 
UK cohort versus 104.1 (98.7) days in the global cohort 
(excluding the UK).
Discontinuations (UK cohort)
A total of 365 patients (89.0%) completed the observation 
period (August 31, 2011). The remaining patients (n=45; 
11.0%) discontinued the study prior to this for a number of 
reasons, including permanent discontinuation of anti-VEGF 
(n=34; 8.3%) (due to treatment failure [n=22], patient deci-
sion [n=2], stable disease [n=6], and other reason [n=4]), 
change of treating physician (n=5; 1.2%), withdrawal by 
patient (n=1; 0.2%), lost to follow-up (n=1; 0.2%), other 
reason (n=3; 0.7%), and missing (n=1; 0.2%).
Discussion
Patients from AURA who were diagnosed with nAMD and 
treated with ranibizumab by their own ophthalmologists 
according to routine practice were retrospectively moni-
tored to determine long-term effectiveness of ranibizumab 
from a UK perspective. Compared with the global popula-
tion, the UK-specific outcomes were better and may have 
been achieved by higher monitoring and retreatment rates. 
Also, most patients in the UK (86.6%) received a loading 
phase (ie, three injections within 90 days), which is more 
than was observed in the global population (80.2%). The 
improvement in visual acuity was higher in patients who 
received a loading phase in both populations, but there was 
still decline over time, which was more marked in the global 
population. Patients in the UK cohort were monitored more 
frequently than in the global population. The mean number 
of ophthalmology visits in years 1 and 2 was 10.4 and 8.0 in 
the UK compared with 8.6 and 4.9 in the global population, 
respectively. The mean number of injections was also higher 
in the UK (5.8 in year 1 and 3.2 in year 2) compared with the 
global population (5.0 in year 1 and 2.2 in year 2). 
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Figure 2 Change in visual acuity score at year 1, year 2, and overall in the UK cohort and global aUra based on visual acuity severity (by letter score) at baseline.
Note: Data are based on effectiveness analysis sets.
Abbreviation: lOCF, last observation carried forward.
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Figure 3 Time from diagnosis to treatment in the UK cohort (n=410; effectiveness 
analysis set).
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These findings reflect how ranibizumab injection 
frequency and long-term monitoring affect visual outcomes 
in real-life, and are an indication of how the UK situation 
compares with the outcomes from other countries. Although 
less frequent ranibizumab dosing is not as effective as 
monthly dosing, four to five injections in the 9 months fol-
lowing a 3-month loading phase is still expected to maintain 
visual acuity based on clinical study outcomes. The CATT 
study showed that the mean change in visual acuity was +8.8 
letters with monthly ranibizumab (mean number of injections 
was 22.4) and +6.7 letters with PRN ranibizumab (mean 
number of injections was 12.6) over a 2-year period.14 In the 
ANCHOR study, ranibizumab 0.5 mg monthly was associ-
ated with a mean change in visual acuity of +11.3 letters in 
year 1 and +10.7 letters in year 2.2,15 The corresponding values 
in the MARINA study were +7.2 letters in year 1 and +6.6 
in year 2.3 In comparison, the current observational study 
showed that the mean change in visual acuity was +6.8 letters 
in year 1 and +4.8 letters in year 2 (with a loading phase), 
with an average of nine injections over a 2-year period.
Observational studies and outcome data from real-life 
clinical practice remain limited. The EMR study, a national 
nAMD database study of ranibizumab in the UK that included 
information from 11,135 patients (12,951 eyes) and more 
than 300,000 clinic visits showed that mean visual acuity 
only improved by +2 letters at the end of year 1 and by +1 
letter at the end of year 2 (the mean baseline visual acuity was 
55 letters).16 However, the median number of visits and injec-
tions were similar to those observed in the current study (9.2 
and five in year 1 and 8.2 and four in year 2, respectively). 
The differences in the improvement in visual acuity between 
the present study and the national AMD database study may 
be attributed to differences in the clinical characteristics of 
the sites providing data for the two studies and/or the exclu-
sion criteria applied in AURA, as 40.4% of the cases were 
excluded from the original screened sample in the present 
study, contributing to selection bias. 
A comparison of the UK results with the other individual 
countries in the AURA study (Figure 1C) showed notable dif-
ferences in visual acuity over time, including better outcomes 
with the UK cohort. In the UK, treatment of nAMD with 
appropriate imaging is undertaken to specified standards that 
are agreed with the local National Health Service provider, 
while in other countries, there may be limits in terms of the 
numbers of treatments that may be administered, and monitor-
ing may also occur less frequently. The National Institute for 
Health and Care Excellence criteria17 may have also helped 
select the most appropriate patients for treatment, based on 
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Figure 4 resource utilization (number of visits, tests, and injections) in the (A) UK cohort (n=410); (B) global aUra (n=2,227); and (C) global aUra (excluding UK) 
(n=1,817) during the 2-year period.
Note: Data are based on effectiveness analysis sets.
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guidance TA155, to receive intravitreal anti-VEGF injections: 
patients must have best-corrected visual acuity between 6/12 
and 6/96, with no permanent structural damage to the central 
fovea. Additionally, the lesion size should be #12 disc areas in 
greatest linear dimension. Royal College of Ophthalmologists 
clinical guidelines also specify the need for frequent monitor-
ing and appropriate treatment.6 UK clinical commissioning 
groups conduct regular audits, and it is likely that this results 
in improved adherence with protocols. Consequently, monthly 
monitoring and relatively frequent treatment are likely to be 
more prevalent in the UK, resulting in better functional out-
comes compared with other countries. 
AURA has both strengths and limitations. It was mod-
erately sized, employed a stringent approach to extraction 
of data (ensuring that all clinical information was captured 
at every visit), and involved multiple centers, which were 
geographically dispersed throughout the UK. It may also 
better reflect real-world outcomes than randomized studies, 
and could help inform policy and provide benchmarks for 
UK audits.
Limitations include its retrospective nature, observational 
design, use of different methods for assessing visual acuity 
outcomes (although they were standardized), and its conduct 
between 2009 and 2011; it is likely that with increasing 
experience of anti-VEGF therapy and the addition of other 
therapeutic agents, treatment of nAMD will have changed in 
recent years. A small minority of patients also received other 
treatments. The study also used an LOCF approach, and thus 
excluded data from patients with poorer or declining visual 
outcomes (ie, those who discontinued early due to treatment 
failure or for reasons not stated). However, observational 
data (also reported in the global paper) showed a similar 
pattern in visual acuity outcomes compared with the LOCF 
analysis. In the UK cohort, visual acuity changed from 55.0 
letters (n=408) at baseline to 62.1 letters (+7.1) at year 1 
(n=263) and to 60.8 letters (+5.8 letters) at year 2 (n=209) 
using observational data (data not shown). Furthermore, only 
the treated study eye was included. If patients had bilateral 
disease, then the eye with the worst visual acuity was included 
into the analysis. In the UK cohort, 20.0% of patients had 
bilateral disease. 
There are also limitations associated with evaluating the 
UK subgroup independently of the global population. One 
of the major drawbacks of the UK AURA cohort is that the 
13 centers that were included may not be representative of 
UK practice as a whole. It is likely that only better-organized 
centers with excellent record keeping and adequate research 
staff were recruited to the study. The relatively good results 
seen with ranibizumab in the UK cohort does not exclude 
the possibility that results with ranibizumab over the whole 
of the UK may be closer to those seen in larger real-world 
studies such as the EMR study, which found that real world 
outcomes did not match the results in randomized studies.16 
The ongoing LUMINOUS study (NCT01318941), which 
includes patients from a larger number of UK centers, 
may also provide additional information from a real-world 
perspective. 
In summary, visual outcomes in real-life clinical experi-
ence in the UK cohort of AURA were only slightly lower 
than those initially observed in clinical studies such as 
CATT and MARINA,3,14 but there was still some decline 
over time. This study also showed that anti-VEGF agents 
are effective in patients with poor baseline visual acuity, 
which is similar to what was reported in another UK study.18 
The findings in the UK also highlight the role of the loading 
phase with ranibizumab treatment. This is consistent with 
results observed in interventional studies with ranibizumab 
and bevacizumab.19–21 However, the reasons for this are not 
fully understood, and may be related to a preconditioning 
effect of the loading phase, resulting in modification of 
subsequent disease course. 
Overall, our results demonstrate that good outcomes are 
achievable in real-life settings, particularly if high quality 
control by payers (such as the situation in the UK) means 
that physicians adhere to protocols for monthly monitoring 
(including injections being around or above seven in the 
first year); however, this is associated with high resource 
utilization and increased burden for patients and health 
care providers, and may depend on reimbursement. In coun-
tries where monitoring and treatment were less frequent, 
and audits and funding were limited, visual outcomes were 
poorer and did not reflect the changes seen in clinical studies. 
Further research into optimal treatment regimens and alterna-
tive therapeutic options may help to further improve patient 
outcomes in real-life settings.
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Figure S1 Timeline for study design.
Abbreviations: FPFV, first patient, first visit; LPFV, last patient, first visit; LPLV, last patient, last visit; VEGF, vascular endothelial growth factor.
Retrospective
FPFV =
January 1, 2009
Start of anti-VEGF
therapy with ranibizumab
Follow-up Data collection
LPFV =
August 31, 2009
LPLV =
August 31, 2011 September 31, 2012
